AffiliationDivision of Molecular and Clinical Cancer Sciences, University of Manchester, Manchester, UK
MetadataShow full item record
AbstractDespite its status as the most commonly mutated oncogene in cancer, Ras has long been considered 'undruggable'. In 2019, we will see the first clinical trial results for direct mutant Ras inhibitors, a result of persistent cross-disciplinary research that has been informed by a number of previous clinical and biological failures.
CitationLindsay CR, Blackhall FH. Direct Ras G12C inhibitors: crossing the rubicon. Br J Cancer. 2019;121(3):197-8.
JournalBritish Journal of Cancer
- Inhibition of RAS: proven and potential vulnerabilities.
- Authors: Zuberi M, Khan I, O'Bryan JP
- Issue date: 2020 Oct 30
- Improving Prospects for Targeting RAS.
- Authors: Singh H, Longo DL, Chabner BA
- Issue date: 2015 Nov 1
- The Research Progress of Direct KRAS G12C Mutation Inhibitors.
- Authors: Yang A, Li M, Fang M
- Issue date: 2021
- KRAS: From undruggable to a druggable Cancer Target.
- Authors: Uprety D, Adjei AA
- Issue date: 2020 Sep
- Dueling KRAS<sup>G12C</sup> Inhibitors Achieve Responses.
- Issue date: 2020 Jan